ICMJE DISCLOSURE FORM

Date: 6/13/2021 Your Name: Gregory Botta, MD/PhD Manuscript Title: Tumor Sequencing Identifies SWI/SNF Complex Alterations as a Biomarker of Immunotherapy Efficacy in Pancreatic Cancer Manuscript number: 150453-INS-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None NIH/NCI	LRP KYGF9753
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	

4	Consulting fees	None	
		Natera	Payments for consulting
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,	Natera	Payments for speaking
	manuscript writing or		
	educational events		
6	Payment for expert testimony	X None	
7	Current for attanding	V Nore	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	l an dauchtin an fiduaismu na b	V. News	
10	Leadership or fiduciary role in other board, society,	X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical	X None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	
		CEND Therapeutics	Consulting
		TumorGen Inc	Consulting

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

1200

ICMJE DISCLOSURE FORM

Date: 6/13/2021 Your Name: Shumei Kato, MD Manuscript Title: Tumor Sequencing Identifies SWI/SNF Complex Alterations as a Biomarker of Immunotherapy Efficacy in Pancreatic Cancer Manuscript number: 150453-INS-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	ACT Genomics, Sysmex	Research Funding
2	Devaltion or licenses	Konica Minolta, Omniseq	Research Funding
3	Royalties or licenses	X None	

4	Consulting fees	None	
		Foundation Medicine	Payments for consulting
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	None RocheX None	Payments for speaking
	testimony		
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Æ

ICMJE DISCLOSURE FORM

Date: 6/13/2021 Your Name: Razelle Kurzrock, MD Manuscript Title: Tumor Sequencing Identifies SWI/SNF Complex Alterations as a Biomarker of Immunotherapy Efficacy in Pancreatic Cancer Manuscript number: 150453-INS-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,	Incyte, Genentech	Research funding
	medical writing, article	Merck Serono, Pfizer	Research funding
	processing charges, etc.) No time limit for this item.	Sequenom, Foundation	Research funding
		Guardant, Grifols	Research funding
		Konica Miolta	Research funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).	NIH/NCI	P30 CA023100
		Joan and Irwin Jacobs Fund	
3	Royalties or licenses	X None	

4	Consulting fees	None	
		LOXO, X-Biotech	Payments for consulting
		Actuate, Genentech, Roche, Neomed	Payments for consulting
5	Payment or honoraria for	None	
5	lectures, presentations,		
	speakers bureaus,	Roche	Payments for speaking
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	V Nono	
/	meetings and/or travel	X None	
8	Patents planned, issued or	X None	
	pending		
-			
9	Participation on a Data Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy	CureMatch, CureMetrix	Founder, Board Member
	group, paid or unpaid		
11	Stock or stock options	None	
		IDbyDNA	Equity Interest
		CureMatch	Equity Interest
12	Receipt of equipment,	X None	1/
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

X I certify that I have answered every question and have not altered the wording of any of the questions on this form

Roell me

Date: 6/13/2021 Your Name: Hitendra Patel, MD; Paul Fanta, MD; Suzanna Lee, MPH; Ryosuke Okamura, MD/PhD Manuscript Title: Tumor Sequencing Identifies SWI/SNF Complex Alterations as a Biomarker of Immunotherapy Efficacy in Pancreatic Cancer Manuscript number: 150453-INS-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non- financial interests	X None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Watel Sujanna Lee & Olan At